Histogenics has a new face in the corner office with the appointment of Peter Greenleaf, an AstraZeneca veteran favored by the board for his experience moving products toward commercialization.
The company has its eyes on an end-stage pivotal trial for NeoCart, a device that uses patients’ own cells to regenerate knee cartilage.
Former CEO Patrick O’Donnell last year led the company through a $49 million raise, with funding led by Sofinnova Ventures, in support of Phase III trials of NeoCart. According a spokesperson for the company, Histogenics is facing a "new set of needs and challenges" that warrants new leadership now.
"Peter has a lot of great experience advancing late stage products and growing middle-to-late stage companies into leaders, which made him natural choice and a great fit for Histogenics. We’re very happy to have him on board," said Dr. Garheng Kong, Histogenics board member and Sofinnova Ventures partner.
Natus brings back former president
Natus Medical (NSDQ:BABY) is handing the title of president back to James Hawkins, who held that role before it was given to ex-president & COO John Buhler. Company documents said Buhler "ceased to be employed," on June 6.
Read more
Electromed COO resigns
Dr. James Cassidy resigned as COO of Electromed, but will see the company through a transition period ending June 28, 2013 and will remain on payroll at his current salary for a 60-day period beginning June 3, 2013.
Read more
New faces in the executive team at SteadyMed Therapeutics
SteadyMed Therapeutics named 2 new executives: Dr. Peter Noymer will join the company as CTO & EVP of R&D, and Rick White will take over as VP of business development & commercial operations.
Read more
